Literature DB >> 23647169

The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.

Trevor W Stone1, L Gail Darlington.   

Abstract

Understanding the neurochemical basis for cognitive function is one of the major goals of neuroscience, with a potential impact on the diagnosis, prevention and treatment of a range of psychiatric and neurological disorders. In this review, the focus will be on a biochemical pathway that remains under-recognized in its implications for brain function, even though it can be responsible for moderating the activity of two neurotransmitters fundamentally involved in cognition - glutamate and acetylcholine. Since this pathway - the kynurenine pathway of tryptophan metabolism - is induced by immunological activation and stress, it also stands in a unique position to mediate the effects of environmental factors on cognition and behaviour. Targeting the pathway for new drug development could, therefore, be of value not only for the treatment of existing psychiatric conditions, but also for preventing the development of cognitive disorders in response to environmental pressures.
© 2013 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23647169      PMCID: PMC3831703          DOI: 10.1111/bph.12230

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  157 in total

1.  Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding.

Authors:  Amy C Chess; David J Bucci
Journal:  Behav Brain Res       Date:  2006-04-18       Impact factor: 3.332

2.  Modulators of the kynurenine pathway of tryptophan metabolism: synthesis and preliminary biological evaluation of (S)-4-(ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor.

Authors:  Roberto Pellicciari; Rosa C Rizzo; Gabriele Costantino; Maura Marinozzi; Laura Amori; Paolo Guidetti; Hui-Qiu Wu; Robert Schwarcz
Journal:  ChemMedChem       Date:  2006-05       Impact factor: 3.466

3.  Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum.

Authors:  Arash Rassoulpour; Hui-Qiu Wu; Sergi Ferre; Robert Schwarcz
Journal:  J Neurochem       Date:  2005-05       Impact factor: 5.372

4.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

5.  Early kynurenergic impairment in Huntington's disease and in a transgenic animal model.

Authors:  P Guidetti; P H Reddy; D A Tagle; R Schwarcz
Journal:  Neurosci Lett       Date:  2000-04-14       Impact factor: 3.046

6.  Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis.

Authors:  Klas R Linderholm; Alexandra Andersson; Sara Olsson; Elin Olsson; Ralph Snodgrass; Göran Engberg; Sophie Erhardt
Journal:  Neuropharmacology       Date:  2007-09-20       Impact factor: 5.250

Review 7.  An expanding range of targets for kynurenine metabolites of tryptophan.

Authors:  Trevor W Stone; Nicholas Stoy; L Gail Darlington
Journal:  Trends Pharmacol Sci       Date:  2012-11-01       Impact factor: 14.819

8.  Selective increases in the cytokine, TNFalpha, in the prefrontal cortex of PCP-treated rats and human schizophrenic subjects: influence of antipsychotic drugs.

Authors:  G J Paterson; Y Ohashi; G P Reynolds; J A Pratt; B J Morris
Journal:  J Psychopharmacol       Date:  2006-02-14       Impact factor: 4.153

9.  1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats.

Authors:  Piotr Luchowski; Elzbieta Luchowska; Waldemar A Turski; Ewa M Urbanska
Journal:  Neurosci Lett       Date:  2002-09-13       Impact factor: 3.046

10.  The NMDA agonist D-cycloserine facilitates fear memory consolidation in humans.

Authors:  Raffael Kalisch; Beatrice Holt; Predrag Petrovic; Benedetto De Martino; Stefan Klöppel; Christian Büchel; Raymond J Dolan
Journal:  Cereb Cortex       Date:  2008-05-13       Impact factor: 5.357

View more
  78 in total

Review 1.  Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

Review 2.  The kynurenine pathway and the brain: Challenges, controversies and promises.

Authors:  Robert Schwarcz; Trevor W Stone
Journal:  Neuropharmacology       Date:  2016-08-07       Impact factor: 5.250

3.  Activation of alpha7 nicotinic and NMDA receptors is necessary for performance in a working memory task.

Authors:  David Phenis; Sarah A Vunck; Valentina Valentini; Hugo Arias; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2020-03-11       Impact factor: 4.530

4.  Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia.

Authors:  Buranee Kanchanatawan; Solaphat Hemrungrojn; Supaksorn Thika; Sunee Sirivichayakul; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2017-09-05       Impact factor: 5.590

Review 5.  NAD+ in Brain Aging and Neurodegenerative Disorders.

Authors:  Sofie Lautrup; David A Sinclair; Mark P Mattson; Evandro F Fang
Journal:  Cell Metab       Date:  2019-10-01       Impact factor: 27.287

6.  Attenuating Nicotine Reinforcement and Relapse by Enhancing Endogenous Brain Levels of Kynurenic Acid in Rats and Squirrel Monkeys.

Authors:  Maria E Secci; Alessia Auber; Leigh V Panlilio; Godfrey H Redhi; Eric B Thorndike; Charles W Schindler; Robert Schwarcz; Steven R Goldberg; Zuzana Justinova
Journal:  Neuropsychopharmacology       Date:  2017-01-31       Impact factor: 7.853

7.  Vitamin B6 Reduces Neurochemical and Long-Term Cognitive Alterations After Polymicrobial Sepsis: Involvement of the Kynurenine Pathway Modulation.

Authors:  Lucinéia Gainski Danielski; Amanda Della Giustina; Mariana Pereira Goldim; Drielly Florentino; Khiany Mathias; Leandro Garbossa; Rosiane de Bona Schraiber; Ana Olívia Martins Laurentino; Marina Goulart; Monique Michels; Karina Barbosa de Queiroz; Markus Kohlhof; Gislaine Tezza Rezin; Jucélia Jeremias Fortunato; Joao Quevedo; Tatiana Barichello; Felipe Dal-Pizzol; Roney S Coimbra; Fabricia Petronilho
Journal:  Mol Neurobiol       Date:  2017-09-06       Impact factor: 5.590

8.  Prenatal kynurenine exposure in rats: age-dependent changes in NMDA receptor expression and conditioned fear responding.

Authors:  Michelle L Pershing; David Phenis; Valentina Valentini; Ana Pocivavsek; Derick H Lindquist; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2016-08-16       Impact factor: 4.530

9.  Distress intolerance, kynurenic acid, and schizophrenia.

Authors:  Daniel C Javitt
Journal:  JAMA Psychiatry       Date:  2014-07-01       Impact factor: 21.596

10.  Smaller Dentate Gyrus and CA2 and CA3 Volumes Are Associated with Kynurenine Metabolites in Collegiate Football Athletes.

Authors:  Timothy B Meier; Jonathan Savitz; Rashmi Singh; T Kent Teague; Patrick S F Bellgowan
Journal:  J Neurotrauma       Date:  2016-01-13       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.